- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 6, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-04-25
DOI
10.3389/fonc.2016.00099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing
- (2016) Vicente Valero et al. ANNALS OF SURGERY
- Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative.
- (2016) Michael J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA).
- (2016) Anitra Engebretson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms
- (2015) Vincenza Cifarelli et al. DIABETES
- A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling
- (2015) Bo Kong et al. GUT
- mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
- (2015) Feng Wei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells
- (2014) Hai-zhou Lou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma
- (2014) Wesley K. Utomo et al. CANCER LETTERS
- Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
- (2014) B. Alagesan et al. CLINICAL CANCER RESEARCH
- Targeting mTOR dependency in pancreatic cancer
- (2014) Douglas C Morran et al. GUT
- Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
- (2014) Stephan Kruger WORLD JOURNAL OF GASTROENTEROLOGY
- Diabetes, pancreatic cancer, and metformin therapy
- (2014) Jun Gong et al. Frontiers in Physiology
- Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells
- (2014) Enrique Rozengurt Frontiers in Physiology
- Recent progress in pancreatic cancer
- (2013) Christopher L. Wolfgang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer
- (2013) Stefan Eser et al. CANCER CELL
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- Biopsies: next-generation biospecimens for tailoring therapy
- (2013) Mark Basik et al. Nature Reviews Clinical Oncology
- Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
- (2013) Heloisa P. Soares et al. PLoS One
- Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
- (2013) Zhi-Jun Dai et al. Drug Design Development and Therapy
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer
- (2012) Charles C. Hsu et al. JOURNAL OF GASTROINTESTINAL SURGERY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network
- (2011) Haoqiang Ying et al. Cancer Discovery
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
- (2010) Adem Kalender et al. Cell Metabolism
- Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer
- (2010) E. Rozengurt et al. CLINICAL CANCER RESEARCH
- Metformin: Taking away the candy for cancer?
- (2010) Mathilde Jalving et al. EUROPEAN JOURNAL OF CANCER
- mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
- (2010) Heinz-Josef Klümpen et al. JOURNAL OF CLINICAL ONCOLOGY
- Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
- (2009) K. Kisfalvi et al. CANCER RESEARCH
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
- (2008) I Ben Sahra et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now